Abstract
Interleukin (IL)-27, a member of the IL-12 cytokine family, plays an important and diverse role in the function of the immune system. We have previously demonstrated that IL-27 is an anti-viral cytokine which inhibits HIV-1, HIV-2, Influenza virus and herpes simplex virus infection, and enhances the potential of reactive oxygen species (ROS) generating activity during differentiation of monocytes to macrophages. In this study, we further investigated the mechanism of the enhanced potential for ROS generation by IL-27. Real time PCR, western blot and knock down assays demonstrate that IL-27 is able to enhance the potential of superoxide production not only during differentiation but also in terminally differentiated-macrophages and immature dendritic cells (iDC) in association with the induction of p47phox, a cytosolic component of the ROS producing enzyme, NADPH oxidase, and the increase in amounts of phosphorylated p47phox upon stimulation. We also demonstrate that IL-27 is able to induce extracellular superoxide dismutase during differentiation of monocytes but not in terminal differentiated macrophages. Since ROS plays an important role in a variety of inflammation, our data demonstrate that IL-27 is a potent regulator of ROS induction and may be a novel therapeutic target.
Similar content being viewed by others
Introduction
Interleukin (IL)-27, a member of the IL-6/IL-12 cytokine family, is a heterodimer consisting of Epstein-Barr virus-induced gene 3 (an IL-12 p40-related protein) and IL-27 p28 (an IL-12 p35-related protein)1. It is mainly produced by dendritic cells and macrophages upon stimulation2. Originally identified as a proinflammatory cytokine to induce Th1 responses in T cells2,3,4, IL-27 is also reported to have anti-viral properties including suppression of HIV-1, HIV-2, Hepatitis C virus, Hepatitis B virus and Herpes simplex virus infection5. IL-27 binds to the IL-27 receptor, which is a heterodimer composed of IL-27Rα (T-cell cytokine receptor/WSX-1) and gp130, a common receptor chain for the IL-6 cytokine family1,4, leading to activation of STAT-1 and STAT-36,7,8. The IL-27 receptor is expressed on T-cells, monocytes, neutrophils, B cells, mast cells, hepatocytes, dendritic cells, and macrophages9,10,11,12,13,14,15,16,17. Accumulating evidence suggests that IL-27 may be an attractive candidate as an immune-therapeutic agent against cancer, allergy, autoimmune diseases, and infectious diseases5,18,19,20,21.
Reactive oxygen species (ROS), such as hydroxyl radical hydrogen peroxide, and singlet oxygen, are converted from superoxide that is produced by activation of NADPH-oxidase, a membrane-bound enzyme complex that exists in multiple isoforms. ROS generated from NADPH-oxidase plays an important role to protect against infection as well as regulation of signal transduction22,23. NADPH-oxidase family enzymes include NADPH-oxidase-1 to NADPH-oxidase-5 and DUOX1/2. NADPH-oxidase-2 is expressed on phagocytes and is composed of a total seven subunits: p22phox, p40phox, p47phox, p67phox, gp91phox, GTPase/Rac1 and GTPase/Rac2. The gp91phox and p22phox subunits are located on the plasma membrane24, while the other subunits localize in the cytoplasm. Rac1 and Rac2 are components of the activated NADPH oxidase complex in monocytes/macrophages and neutrophils, respectively25,26,27.
Upon stimulation, p47phox is phosphorylated via a kinase and the phosphorylated p47phox migrates to the plasma membrane where it associates with gp91phox and p22phox to form an active enzyme complex. Increased phosphorylation of p47phox leads to increased activity of NADPH-oxidase and higher levels of ROS. Multiple phosphorylation sites, such as amino acid serine (Ser) at position 303, 304, 328, 358, and 370, in p47phox have been identified as being important sites in assembling the NADPH-oxidase complex28. Simultaneous phosphorylation of Ser 303, 304, and 328 unmasks an SH3 domain, resulting in an interaction with p22phox29.
In vitro study, monocytes are differentiated into macrophages using cytokines30,31. GM-CSF and M-CSF-induced macrophages are known as M-1 and M-2 macrophages, respectively. We have previously demonstrated that anti-HIV cytokine, IL-27 promotes macrophages into HIV-resistant macrophages (I-Mac) during differentiation from monocytes without an obvious impact on phagocytosis, chemotaxis, production of pro-inflammatory cytokines such as IL-8, IL-10, TNF-α or MCP-1, and the expression of macrophage differentiation markers such as CD14, CD11B, EMR1 or CD20632. Of note, the HIV-resistant I-Mac possess a higher level of potential to produce ROS upon PMA stimulation compared to untreated macrophages and it has been reported that ROS in macrophages is essential for uptake and clearance of apoptotic cells33,34. In addition, a recent study reported that the inhibition of ROS production blocks differentiation of tumor-associated macrophages and M-CSF-induced monocyte-derived macrophages35, thus the enhanced potential of superoxide production in I-Mac may provide a benefit for macrophage function and differentiation. In the current study, we investigated the pathways involved in IL-27 modulation of macrophage function with respect to superoxide production using several types of macrophages and iDC and identified enhanced expression and phosphorylation of p47phox as playing a key role.
Results
IL-27 treatment enhances potential ROS production associated with increase in p47phox expression
In our previous work, we demonstrated that macrophages differentiated from monocytes in the presence of IL-27 (IL-27-induced macrophages: I-Mac) resist infection of HIV-1, HIV-2, Influenza virus, and Herpes simplex virus, and produced 6-fold higher levels of ROS production upon PMA stimulation than M-CSF-induced macrophages (M-Mac) upon stimulation32. The data indicated that IL-27 enhances potential of superoxide production during differentiation, however, the mechanism underlying this observation has, thus far, remained unclear. To explore the mechanisms beneath the ROS inducing activity of IL-27, we first examined the effects of IL-27 directly on terminally differentiated M-Mac. M-Mac were treated with IL-27 for 0, 24, 48 and 72 h and then stimulated with PMA for 30 min prior to measurement of superoxide as reflected by hydrogen peroxide (H2O2) production. PMA stimulation of IL-27-treated M-Mac enhanced ROS production in a time dependent manner (Fig. 1a). Furthermore, IL-27-treated M-Mac continued to produce ROS for at least 30 min (Fig. 1b). This indicates that IL-27 is able to enhance the potential for ROS production by even fully differentiated macrophages.
The induction of ROS from phagocytes is mediated by NADPH-oxidase-2. To confirm whether or not the enhanced ROS induction from IL-27-treated M-Mac is mediated by NADPH-oxidase-2, we evaluated the impact of apocynin and diphenylene iodonium (DPI) on the superoxide production. Apocynin is a specific inhibitor of NADPH oxidase-236. DPI inhibits NADPH oxidase-2 by removing an electron from the reduced NADPH-oxidase enzyme37. As shown in Fig. 1c,d, although trypan blue exclusion assay demonstrated any significant cell toxicity (data not shown), the production of ROS was dose-dependently suppressed by either apocynin or DPI implicating NADPH oxidase-2 as a critical mediator of this activity.
NADPH oxidase-2 is composed of p22phox, p40phox, p47phox, p67phox, gp91phox, and Rac1/2 subunits. To determine if IL-27-mediated ROS enhancement was due to an increase in some of the subunits of NADPH oxidase-2, we examined the relative levels of gene expression of each subunit of NADPH oxidase-2 in IL-27-treated and untreated M-Mac. The expression of the p47phox gene was increased approximately 12-fold (P < 0.01) and Rac2 gene was downregulated by near 50% (p < 0.05) in IL-27-treated M-Mac compared to untreated M-Mac, however, the expression of other subunits was not significantly changed (Fig. 1e). The increase in p47phox gene expression was associated with an increase in p47phox protein expression (Fig. 1f and Supplementary Fig. S1) by 2.01 ± 0.11 (n = 5) fold. To further characterize the gene induction by IL-27, time course and dose response analyses were performed. The endogenous expression of p47phox was decreased in untreated cells after 24 h incubation (p < 0.01), while the expression level of p47phox in IL-27-treated cells was increased, rather than maintained, in a time dependent manner (Fig. 1g) (p < 0.01). The induction was saturated at more than 30 ng/ml of IL-27 at 48 h incubation (Fig. 1h). In our previous work, we have used 100 ng/ml of IL-27 to stimulate macrophages or differentiate monocytes into macrophages13,32,38,39, thus in this study, we used the same concentration of IL-27 in downstream experiments. Translational inhibitor Cycloheximide (CHX) was used to define whether the increase in p47phox protein is associated with de novo synthesis or protein stability. CHX inhibited the p47phox protein expression dose dependent manner (Fig. 1i) with the accumulation of p47phox mRNA (Fig. 1j). Taken together, these data suggesting that IL-27-mediated increase in p47phox is associated with induction of p47phox transcripts rather than either stabilization of the p47phox mRNA or p47phox protein. In this study, superoxide produced by NADPH oxidase-2 was monitored by detecting produced H2O2. The superoxide is catalyzed into H2O2 by super oxide dismutase (SOD)40, therefore, it was considered that the augmented H2O2 production may be associated with the increase in SOD expression in IL-27-treated M-Mac. To define the role of IL-27 on the expression of SOD, western blot analysis was performed. SOD exists in three isoforms in mammals: the cytoplasmic Cu/Zn-SOD (SOD1), the mitochondrial Mn-SOD (SOD2), and the extracellular Cu/Zn-SOD (SOD3)41, thus, the expression level of the three isoforms in IL-27-treated M-Mac were compared to that in untreated M-Mac. The Western blot analysis revealed that none of the isoforms were significantly changed in IL-27-treated M-Mac as compared to untreated M-Mac (Fig. 1k and Supplementary Fig. S2).
We have previously demonstrated that IL-27 induced macrophages (I-Mac) resist HIV infection32. To elucidate whether or not the IL-27-treated M-Mac possess resistance to HIV infection as I-Mac does, anti-HIV effect was evaluated. IL-27-treated M-Mac or untreated M-Mac were infected with HIV-1 and the amount of HIV-1 p24 released into the supernatant was assessed. HIV-1 infection of I-Mac was also analyzed as a control. As shown in Fig. 1l, the IL-27-treated cells demonstrated HIV resistance as I-Mac, indicating that IL-27 is able to induce HIV-resistance property in terminally differentiated macrophages.
Having established that IL-27 has an effect on p47phox gene expression, we next sought to determine the signaling pathway involved in this modulation. IL-27 is known to trigger JAK1 and JAK2 activation followed by STAT-1, -3 and -5 signaling pathway2. In our previous work, we demonstrated that IL-27 induces TGF-β activated kinase-1 (TAK-1) signaling pathway in M-Mac32. To determine which pathway is involved in the p47phox expression and superoxide production, we performed inhibition assays. Prior to the IL-27 treatment, M-Mac were pre-incubated with JAK inhibitors and then p47phox expression and superoxide production were analyzed. 1 μM of Ruxolitinib (JAK1/2 inhibitor) and 5 μM of Tofacitinib (JAK1/3 inhibitor) suppressed the IL-27-mediated STAT-1, -3 and -5 activation (Supplementary Fig. S3) without any significant change in cell viability (data not shown). Using this concentration of inhibitors, p47phox expression and superoxide production were analyzed. Both JAK inhibitors abolished the IL-27-mediated induction of p47phox gene activation, protein production (Fig. 2a,b) and PMA-stimulated superoxide production (Fig. 2c). To address a role of TAK-1 pathway in the p47phox induction and superoxide production, M-Mac were treated with a small interfering RNA (siRNA) against TAK-1 (si-TAK-1) or NG25, a TAK-1 specific inhibitor. Although 100 pmol of si-TAk-1 knocked down TAK-1 expression by 77% (Fig. 2d), the knockdown had no impact on either the induction of p47phox expression or superoxide production (Fig. 2d,e), even TAK-1 expression was knocked down, superoxide production was induced by ~6-fold compared to unstimulated cells as si-Ctrl treated cell does. 100 nM of NG25 treatment abrogated TAK-1 mediated activation of p38 MAPK (Supplementary Fig. S4a) without any significant changes in IL-27-mediated p47phox induction and superoxide production (Supplementary Fig. S4b,c). Taken together, these data indicate that the JAK/STAT, but not TAK-1 pathway plays a pivotal role in IL-27-mediated p47phox induction.
Direct impact of knockdown or overexpression of p47phox on Superoxide production
To further examine the direct role of p47phox in the IL-27 associated increase in generation of ROS following PMA stimulation, p47phox was knocked down using si-RNA against p47phox (si-p47). Cells treated with si-p47 had significantly lower expression of p47phox (Fig. 3a) (10% of expression of p47phox as compared to control), and significantly decreased the amounts of PMA-induced ROS production (p < 0.01) (Fig. 3b). To determine the impact of overexpression of p47phox, a p47phox expression vector was constructed and transfected into M-Mac followed by measuring PMA-induced superoxide production. The expression vector enhanced p47phox expression by 4-fold (Fig. 3c), and PMA-induced superoxide production was enhanced by 6-fold (Fig. 3d) as compared to un-transfected cells (p < 0.01). Thus, the increased expression of p47phox even in the absence of IL-27 leads to an enhancement in ROS production from macrophages.
IL-27 treatment of macrophages from a p47phox-/- CGD patient fails to induce reactive oxygen species
One form of chronic granulomatous disease (CGD) is caused by missense, nonsense, frame shift, splice, or deletion mutations in p47phox, resulting in impaired production of ROS42. To further define the role of IL-27 in enhancing the potential for ROS production, superoxide production was analyzed from IL-27 stimulated macrophages derived from a p47phox−/− patient. This patient’s cells lack the expression of p47phox as compared to a healthy donor (Supplementary Fig. S5). Other NADPH oxidase-2 subunits (gp91phox, p67phox, p40phox, p20phox and Rac1) were expressed to comparatively similar levels as a healthy donor (Supplementary Fig. S5). IL-27 treatment of p47phox−/− macrophages failed to induce either p47phox expression (Fig. 3e) or ROS production (Fig. 3f,g). These data strongly suggest that p47phox is a critical mediator of the effect of IL-27 on PMA-induced superoxide production.
IL-27-enhanced PMA-induced phosphorylation of p47phox is required for Superoxide production
In addition to increasing total levels of p47phox, it is possible that IL-27 might modulate p47phox activity by influencing its phosphorylation. An increase in p47phox phosphorylation is associated with enhanced superoxide production28. Therefore, we compared the phosphorylation of p47phox between IL-27-treated and untreated macrophages. Both macrophages were stimulated with PMA for 20 min and whole cell lysates were prepared after 0, 5, 10 and 20 min stimulation and then phosphorylation of p47phox was analyzed by western blot. Before PMA stimulation, phosphorylation at S328 or S304 on p47phox was not detected in both untreated and IL-27-treated M-Mac. After 5 min of PMA-stimulation, phosphorylation at S328 was initially induced in both cell types, and then 10 min after the stimulation, the amount of phosphorylation in untreated cells was reduced, while the amount in the IL-27-treated cells was increased until 20 min stimulation. In addition, the phosphorylation at S304 was increased in the IL-27-treated macrophages (Fig. 4).
IL-27-induced macrophages promotes p47phox expression and enhance potential superoxide production
In our previous work, we demonstrated that macrophages differentiated in the presence of IL-27 (I-Mac) resist HIV and other viral infections32. In addition, the potential of superoxide production was enhanced in the cells32. To precisely compare the potential of superoxide production among M-Mac, I-Mac, untreated M-Mac and IL-27-treated M-Mac, these cell types were generated from the same lot of monocytes, and then p47phox protein expression and superoxide production were compared. I-Mac and IL-27-treated M-Mac produced 5- and 2-fold higher levels of ROS as compared to M-Mac and untreated M-Mac, respectively (Fig. 5a). In addition, protein amounts of p47phox was enhanced in I-Mac and IL-27-treated M-Mac by 6- and 2-fold, respectively (Fig. 5b). To illustrate phosphorylation level of p47phox, PMA-stimulated and unstimulated cells were lysed and 2D Western blot analysis was performed using the lysate. Cell lysate from PMA-stimulated I-Mac resulted in smearing p47phox band shifting to (+) side on the gel (Fig. 5c). This result indicated that PMA-stimulated cells may contain highly phosphorylated p47phox forms. To define whether the smear band is associated with an increase in phosphorylation, 2D-western blotting was performed using anti-phosphorylated S304 p47phox antibody. The p47phox band was detected only in a cell lysate from PMA-stimulated I-Mac. To further demonstrate that the migration toward (+) side is caused by phosphorylation rather than some other modification of p47phox, a cell lysate from the PMA-stimulated I-Mac were treated with or without Lambda protein phosphatase in vitro, and then were subjected to 1D and 2D western blot. The phosphatase treatment decreased the level of phosphorylated p47phox in the 1D western blotting (supplementary Fig. S6a) and suppressed the shift of the p47phox band to (+) side (Supplementary Fig. S6b). Taken together, these results illustrate that PMA–stimulated I-Mac express higher levels of phosphorylated p47phox than M-Mac. As shown in Fig. 1k, IL-27 has no impact on the expression of the three isoforms of SOD in terminally differentiated macrophages. To define the role of IL-27 on SOD expression during monocytes differentiation, the expression was compared between M-Mac and I-Mac by Western blot. Although SOD1 expression was unchanged, of interest, the protein expression level of SOD2 and SOD3 in I-Mac were increased by 2.5 ± 0.6 (n = 4, p < 0.01) and 4.7 ± 2.3 (n = 4, p < 0.01), respectively (Fig. 5d and Supplementary Fig. S7) compared to M-Mac.
IL-27 treatment enhances potential ROS production in iDC and other monocytes-derived macrophages
In addition to M-CSF induced macrophages (M-Mac), the NADPH-oxidase-2 family of enzymes is also found in GM-CSF induced macrophages (GM-Mac) and monocyte derived dendritic cells (iDC)43,44. M-Mac, GM-Mac and iDC were differentiated from a same lot of monocytes and then treated with IL-27 to determine each cell type’s ability to induce p47phox expression and subsequent superoxide production in response to PMA. Following their respective differentiation, M-Mac, GM-Mac and iDC were exposed to IL-27 for 48 h prior to analysis for p47phox and gp91phox induction and ROS production. M-Mac, GM-Mac and iDC all revealed increased amounts of p47phox mRNA following IL-27 exposure (Fig. 6a). The mRNA level of gp91phox also increased in only iDC. Induction of the p47phox mRNA in GM-Mac and iDC corresponded to an increase in p47phox protein expression (Fig. 6c). IL-27 treatment of GM-Mac and iDC revealed a 1.7 and 10.1-fold increase in p47phox protein expression, respectively (Fig. 6b). A 1.5-fold increase in gp91phox protein level was observed in iDC treated with IL-27 as compared to untreated iDC. The relative potential ROS production of GM-Mac, M-Mac and iDC were also measured following IL-27. Exposure of cells to PMA for 30 min following IL-27 treatment of M-Mac, GM-Mac and iDCs induced ROS production by 60, 165 and 12-fold compared to untreated cells, respectively (Fig. 6c). These findings show that IL-27 is able to increase p47phox expression in differentiated GM-Mac and iDC as well as M-Mac and that this increase is associated with an enhanced potential for superoxide production.
Discussion
IL-27 has emerged as an important immunomodulatory cytokine playing pivotal roles in both innate and adaptive immunity5. Our previous studies reported that IL-27 differentiates monocytes into HIV-resistant macrophages (IL-27-induced Mac: I-Mac) and enhanced a potential activity of superoxide production in the cells upon PMA stimulation32, suggesting that IL-27 enhances a potential of ROS inducing activity during differentiation. In this study, we have further demonstrated that IL-27 is able to increase the potential for superoxide production even in terminally differentiated macrophages, in addition, IL-27 treatment leads to HIV resistance in the terminally differentiated M-CSF-induced macrophages, indicating that IL-27 is able to modulate macrophage functions during and after differentiation. Furthermore, this increase in the potential for superoxide production is associated with an induction of p47phox, a component of the NADPH-oxidase-2 complex. This augmentation is mediated via JAK/STAT pathway and increase in phosphorylation of p47phox (Fig. 7). The p47phox was augmented in all tested macrophages subtypes (M-mac and GM-mac). We observed an increase in p47phox at the mRNA and protein levels, silencing of p47phox in IL-27-treated M-Mac suppressed superoxide production, and IL-27 failed to induce ROS activity from p47phox−/− macrophages derived from a CGD patient with a genetic defect in p47phox. Of note, transfection of a p47phox expression plasmid in M-Mac increased the p47phox expression by 4-fold, but it only enhanced ROS production by 2~3-fold, since IL-27 treatment had no impact on SODs expression, the data suggest that other factors in addition to p47phox induction may be involved in the enhancement of potential of superoxide production in IL-27-treated cells. Despite the fact that IL-27 increases the p47phox expression, without a stimulation, IL-27-treated and untreated cells had indistinguishable levels of spontaneous superoxide production. Therefore, the increase in potential of superoxide production may not directly influence macrophage differentiation and function without stimulation. In this study, the potential for superoxide production by NADPH oxidase activity was monitored by detecting H2O2 production. The produced superoxide is catalyzed to H2O2 by SOD41, therefore, it was considered that the increase in H2O2 production may be associated with increase in SOD expression. Although IL-27-treated M-Mac demonstrated little if any change on the expression of all three types of SOD isoforms, of note, in I-Mac, the expression of SOD2 and SOD3, but not SOD1, were significantly increased compared to that in M-Mac. ROS production from I-Mac was relatively higher than that from M-Mac. It is known that SOD2 plays a key role on mitochondrial NADPH oxidase activity41, thus it is possible that the increase in the SOD2 expression in I-Mac contributes in the enhanced ROS production. SOD3 was originally discovered as a secreted, extracellular protein45, however, current studies demonstrate that SOD3 is expressed on the cell surface46,47,48. Thus the induced SOD3 may also contribute to the enhanced ROS production by I-Mac. Additionally, it was reported that SOD3 on macrophage is associated with strong bacterial killing by phagocytosis47. Thus, IL-27-indcued macrophages (I-Mac) may also possess an increased anti-bacterial activity. Further study may define the mechanism of SOD3 induction in I-Mac and delineate insight of a role of SOD3 in virus infection in macrophages.
Real time PCR and western blotting confirmed that IL-27 induced p47phox during and/or after differentiation of monocytes to macrophages and iDC. This increase corresponded to enhancement of superoxide production upon stimulation in all cell types. These findings suggest that IL-27 may be capable of enhancing ROS production in myeloid lineage including microglia cells49. IL-27 treatment enhanced the expression of gp91phox mRNA in only iDC; however, this induction did not correspond with protein induction. The potential activity of superoxide production was compared among M-Mac, GM-Mac and iDC. Despite the fact that IL-27 treatment induced p47phox in all these cells types, the induction level of ROS from iDCs was 1/10~1/20 compared to the level from M-Mac and GM-Macs. To further delineate the ability of IL-27 on p47phox induction in different types of macrophages, p47phox expression was analyzed on macrophages differentiated in the presence of GM-CSF and IL-27 (I-GM-Mac). To precisely compare the IL-27 effect on different macrophages, monocytes from the same lot of donors were differentiated into M-Mac, I-Mac, GM-Mac and I-GM-Mac. Western blot analysis revealed that the expression of p47phox protein was enhanced by 5.2 + 1.9-fold (p < 0.01, n = 4) in I-Mac and by 3.9 + 1.4-fold (p = 0.051, n = 4) in I-GM-Mac (Supplementary Fig. S8), suggesting that IL-27 is able to induce p47phox during I-GM-Mac differentiation. Further study is needed to define the mechanism underlying these differences among these cell types.
To define whether or not IL-27 induced p47phox expression is caused by the induction of transcripts or the stabilization of p47phox mRNA, time course and dose response assays were performed. In untreated cells, the endogenous expression of level of p47phox mRNA was time-dependently decreased, whereas, in IL-27-treated cells, the expression level was increased by time dependent and a dose dependent manner and the induction was inhibited by JAK but not TAK1 inhibitors. A translational inhibitor, CHX, treatment decreased the p47phox protein amount along with accumulation of p47phox mRNA. Taken together, IL-27 induces the p47phox mRNA expression rather stabilize either mRNA or protein. Further study may need to elucidate a molecular mechanism of the IL-27-mediated p47phox induction. IL-27 belongs to the IL-6 family cytokine based on gp130 usage. The IL-6 family is composed of IL-6, IL-11, IL-27, IL-31, IL-35, leukemia inhibitory factor (LIF), Oncostatin M (OSM), and ciliary neurotrophic factor (CNTF), and induces activation of STAT-1, 3, and 550,51,52. To determine whether or not those cytokines rather than IL-27 also increase in p47phox expression, we incubated macrophages with a variety of cytokines and then analyzed p47phox gene expression. IL-27 was the only clear inducer of p47phox in this family (Supplementary Fig. S9), suggesting that IL-27 may differentially regulate signal transduction via gp130.
In our previous study (29), we demonstrated that IL-27 induces HIV resistance in macrophages with an enhancement of potential of superoxide production. In this study we demonstrated IL-27 is able to enhance the potential in not only M-CSF-induced macrophages, but also GM-CSF-induced macrophages and dendritic cells, therefore, further study of role of IL-27 on the differentiated macrophages and dendritic cell may shed light on a new physiological function of IL-27. ROS plays a significant role in a variety of inflammatory diseases and it is noted that ROS in macrophages is essential for uptake and clearance of apoptotic cells33,34 and ROS production is an essential factor for differentiation of macrophages35, thus enhanced potential of superoxide production by IL-27 may provide a benefit for macrophage function and differentiation. IL-27, a potent regulator of ROS production in myeloid lineage cells, may be a novel therapeutic target for one or more of these conditions.
Methods
Approval for these studies including all sample materials was granted by the National Institute of Allergy and Infectious Diseases Institutional Review Board and participants were informed written consent prior to blood being drawn. Participants were informed written consent prior to blood being drawn. All experimental procedures in these studies were approved by the National Cancer Institute at Frederick and performed in accordance with the relevant guidelines and regulations.
Cells and reagents
CD14+ monocytes were purified from PBMCs of healthy donors using CD14 MicroBeads (Miltenyi Biotec) according to the manufacturer’s instructions as previously described38. Approval for these studies was granted by the National Institute of Allergy and Infectious Diseases Institutional Review Board. Participants were informed written consent prior to blood being drawn. To generate M-CSF induced macrophages (M-Mac) or GM-CSF-induced macrophages (GM-Mac), the isolated CD14+ monocytes were cultured for 7 days in the presence of 25 ng/ml M-CSF (R&D systems) or 50 ng/ml of GM-CSF (R&D systems) in macrophage serum-free medium (Thermo Fisher Scientific) supplemented with 10 mM HEPES and 5 μg/ml of Gentamycin. IL-27-induced macrophages (I-Mac) were generated from the CD14+ monocytes by culturing for 7 days in the presence of 25 ng/ml of M-CSF with 100 ng/ml of IL-27 (R&D systems)32. M-Mac and I-Mac were then maintained in D-10 medium [D-MEM (Thermo Fisher Scientific) containing 10% FBS (HyClone Laboratories), 25 mM HEPES, and 5 μg/ml Gentamicin. To induce immature dendritic cells (iDC), CD14+ monocytes were cultured at 0.5 × 106 cells/ml for 7 days in the presence of 50 ng/ml GM-CSF, 50 ng/ml of IL-4 (R&D systems) in RPMI-1640 (Thermo Fisher Scientific) with 10% FBS, 10 mM HEPES, and 5 μg/ml of Gentamycin (G4 media)13. Cell viability was determined by trypan blue exclusion assay using a final 0.2% trypan blue solution (Thermo Fisher Scientific). JAK inhibitors, Ruxoliotinib and Tofacitinib53 were obtained from Selleckchem. A translational inhibitor, cycloheximide was obtained from Sigma-Aldrich. Anti-SOD1 antibody (#2770), anti-SOD2 antibody (#13194), anti-p47phox antibody (#4312) and anti-phosphorylated p38MAPK antibody (#4511) were obtained from Cell Signaling. Anti-phosphorylated p47phox antibodies (ab63554 and ab111855) and anti-gp91phox antibody (ab31092), and anti-p40phox antibody (ab2244) were purchased from Abcam. Anti-Rac1 antibody (# 05-384) and Anti-β-actin antibody (AC-15) was purchased from EMD Millipore and SantCruz, respectively. Si-RNA against TAK-1 (#s13788) was obtained from Thermo Fisher Scientific.
Superoxide Production Assay
Superoxide producing activity were determined by measuring levels of hydrogen peroxide (H2O2) using the Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Thermo Fisher Scientific). Briefly, macrophages or dendritic cells were seeded in 96 well plates (5 × 104 cells/well for macrophages and 1 × 105 cells/well for iDC) in D-10 or G4 media, respectively, and incubated at 37 °C overnight in 5% CO2. Cells were then washed 3X with warmed Krebs–Ringer phosphate buffer (145 mM NaCl, 5.7 mM sodium phosphate, 4.86 mM KCl, 0.54 mM CaCl2, and 1.22 mM MgCl2) supplemented with 5.5 mM Glucose and then incubated in the buffer for 30 min at 37 °C before stimulation. For stimulating and detecting ROS production, 50 μL of prewarmed 2xAmplex Red reagent (Thermo Fisher Scientific) containing 200 ng/mL PMA (Sigma-Aldrich) was added to each well and the plates incubated for 30 min at 37 °C. As a control, some wells did not receive PMA. The induced H2O2 was measured at 560 nm in a 96 well plate reader (PerkinElmer). To quantitate the produced H2O2, 20 mM stable H2O2 (Thermo Fisher Scientific) was used for a standard.
HIV replication assay
Macrophages were infected with HIV as previously described32. Briefly, M-Mac, I-Mac, or IL-27 treated cells 5 × 106 cells were incubated with 5000 TCID50 HIV-1BAL (Advanced Biotechnologies, Inc) for 2 h. The HIV infected cells were cultured for 14 days in D-10 media in 96 well plates. Half culture supernatants were replaced with fresh media every 3 or 4 days. HIV replication activity was monitored using an HIV p24 antigen capture kit (Perkin-Elmer).
Construction of p47phox expression plasmid
The p47phox expression plasmid (pCMVp47Phox) was conducted as follows: p47phox cDNA was synthesized from 5 μg of total cellular RNA derived from macrophages using the Superscript First Stand Synthesis System for RT-PCR (Thermo Fisher Scientific). PCR amplification of the cDNA using the PCR primer pair: 5′-AGC CGC CAT GGG GGA CAC CTT CAT C-3′ and 5′-GGT ACC CTA GAC GGC AGA CGC CAG CTT CCG CTT G-3′ with the Expand High fidelity PCR system (Roche Molecular Diagnostics). The PCR product was ligated into pCR2.1 and confirmatory DNA sequencing was performed using BigDye 3 with ABI Prism 3130X Genetic Analyzer. The p47phox gene intended gene was then subcloned into pCMV5a (Sigma-Aldrich) to generate pCMVp47Phox.
Quantitative RT-PCR
Macrophages or iDCs were washed with cold PBS (Quality Biology) and RNA was isolated from the cells using the RNeasy Isolation kit (Qiagen). Total cDNA was then synthesized using Taqman reverse transcription reagents (Thermo Fisher Scientific) with random hexamer priming. Expression levels of the genes of interest were measured by semi-quantitative RT-PCR by a CFX96 Real-Time system (BioRad). The level of gene expression were normalized to GAPDH. Probes specific for each subunit of NADPH oxidase, p91phox (Hs00166163_m1), p22phox (Hs00164370_m1), p40phox (Hs00241129_m1), p47phox (Hs00165362_m1), p67phox (Hs01084940_m1) and GAPDH (Hs99999905_m1) were purchased from Thermo Fisher Scientific.
DNA transfection of Macrophages
DNA transfection of macrophages was performed using 4D-Nucleofector system (Lonza) with the P3 Primary Cell Kit (V4SP-3096) (Lonza). Macrophages (6 × 105 cells) were mixed with 2 μg pCMVp47phox or empty vector in 100 μL of P3 primary cell solution. Cells were transfected using the 4D-Nucleofector program DP-148. After transfection, cells were cultured in D-10 for 7 h at 37 °C and then assayed for ROS as described above. The expression of p47phox was confirmed by western blot analysis.
Silencing of p47phox or TAK-1 in Macrophages by siRNA
Macrophages were transfected with p47phox specific siRNA (#4392420, Thermo Fisher Scientific) or scrambled control siRNA (SR30004, Origene) using Lipofectamine 2000 (Thermo Fisher Scientific)32. Briefly, MDMs (0.6 × 106/well) were seeded in a 24-well plate. 50 pmol siRNA and 3 μL Lipofectamine 2000 were mixed in 350 μL plain DMEM. The transfection mixture was incubated at room temperature for 30 min. Macrophages were washed with plain DMEM once and then incubated with the transfection mixture at 37 °C. After 2 h, the transfection mixture was removed and replaced with D-10 media. The level of p47phox knockdown was assessed by RT-PCR and Western blotting 48 h post transfection. TAK-1 specific siRNA (#4390824, Thermo Fisher Scientific) was transfected into macrophages using the 4D-Nucleofector system with the P3 primary cell kit (Lonza)32. M-Mac was transfected with 100 pmol of siRNA following a transfection protocol by the vendor, and then cultured for 48 h. The cells were treated with or without 100 ng/ml of IL-27 for another 48 h and then subjected to western blot for the detection of TAK-1 protein or ROS assay as described above.
SDS-PAGE and Western blot analysis
Macrophages or iDCs (1.5 × 106 cells) were seeded in 6-well plates and cultured in 3 mL of D-10 or G4 media at 37 °C. To obtain whole-cell extracts for SDS-PAGE, cells were washed with ice-cold PBS, and resuspended in RIPA buffer (Boston Bioproduct) with protease inhibitor cocktail (Sigma Aldrich) and phosphatase inhibitors (Thermo Fisher Scientific) at 4 °C for 10 min. The protein concentration was determined using the bicinchoninic acid (BCA) protein assay kit (Thermo Fisher Scientific). Using a total of 25 μg protein, Western blot analysis was performed as previously described32. Antibody binding was visualized using the ECL Prime Western Detection Reagent (GE-Healthcare) and LAS-4000 (Fujifilm, Tokyo, Japan). The intensity of the band was analyzed by NIH Image J (http://rsbweb.nih.gov/ij/).
2D-PAGE and Western blot analysis
Whole cell lysate protein (100 μg) were subjected for 2D-PAGE analysis. For the first dimension of 2D-PAGE, immobilized pH gradient gel strips (pH 6–11, GE Healthcare Bioscience) were used. The samples were mixed with 100 uL of sample buffer and rehydrated for 18 h. The electrophoresis voltage was increased stepwise from 0 to 5,000 or 8,000 V for 3–5 h as recommended by the supplier. Each strip was equilibrated in 50 mM Tris-HCl (pH 8.8) containing 6 M urea, 2% SDS, 30% glycerol, and 20 mM DTE for 20 min. The second-dimension separation was achieved by performing SDS-PAGE in the manner described above. After separation by 2D-PAGE, the samples were transferred to a membrane for western blot analysis.
De-phosphorylation of cell lysate
A total cell lysate (100 μg) from PMA-stimulated I-Mac were treated with 4000 units/ml of Lambda Protein Phosphatase (New England Biolabs) at 37 °C for 60 min in Lambda phosphatase buffer (New England Biolabs) supplemented with protease inhibitor cocktail, and then the lysate was subjected to 2D-PAGE followed by Western blot analysis.
Statistical Analysis
Statistical analyses were performed using GraphPad Prism 5 software. Error bars indicate standard deviations (SD) or standard errors (SE) from means as noted. An unpaired Student’s t test was used and p values lower than 0.05 were considered significance.
Additional Information
How to cite this article: Sowrirajan, B. et al. Interleukin-27 Enhances the Potential of Reactive Oxygen Species Generation from Monocyte-derived Macrophages and Dendritic cells by Induction of p47phox. Sci. Rep. 7, 43441; doi: 10.1038/srep43441 (2017).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
References
Pflanz, S. et al. IL-27, a heterodimeric cytokine composed of EBI3 and p28 protein, induces proliferation of naive CD4(+) T cells. Immunity 16, 779–790, doi: S1074761302003242 (2002).
Kastelein, R. A., Hunter, C. A. & Cua, D. J. Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation. Annual review of immunology 25, 221–242, doi: 10.1146/annurev.immunol.22.012703.104758 (2007).
Villarino, A. V., Huang, E. & Hunter, C. A. Understanding the pro- and anti-inflammatory properties of IL-27. Journal of immunology 173, 715–720 (2004).
Pflanz, S. et al. WSX-1 and glycoprotein 130 constitute a signal-transducing receptor for IL-27. Journal of immunology 172, 2225–2231 (2004).
Swaminathan, S., Dai, L., Lane, H. C. & Imamichi, T. Evaluating the potential of IL-27 as a novel therapeutic agent in HIV-1 infection. Cytokine & growth factor reviews 24, 571–577, doi: 10.1016/j.cytogfr.2013.07.001 (2013).
Hibbert, L., Pflanz, S., De Waal Malefyt, R. & Kastelein, R. A. IL-27 and IFN-alpha signal via Stat1 and Stat3 and induce T-Bet and IL-12Rbeta2 in naive T cells. J Interferon Cytokine Res 23, 513–522 (2003).
Kamiya, S. et al. An indispensable role for STAT1 in IL-27-induced T-bet expression but not proliferation of naive CD4+ T cells. Journal of immunology 173, 3871–3877 (2004).
Takeda, A. et al. Cutting edge: role of IL-27/WSX-1 signaling for induction of T-bet through activation of STAT1 during initial Th1 commitment. Journal of immunology 170, 4886–4890 (2003).
Chiyo, M. et al. Expression of IL-27 in murine carcinoma cells produces antitumor effects and induces protective immunity in inoculated host animals. International journal of cancer. Journal international du cancer 115, 437–442, doi: 10.1002/ijc.20848 (2005).
Hisada, M. et al. Potent antitumor activity of interleukin-27. Cancer research 64, 1152–1156 (2004).
Salcedo, R. et al. Immunologic and therapeutic synergy of IL-27 and IL-2: enhancement of T cell sensitization, tumor-specific CTL reactivity and complete regression of disseminated neuroblastoma metastases in the liver and bone marrow. Journal of immunology 182, 4328–4338, doi: 10.4049/jimmunol.0800471 (2009).
Salcedo, R. et al. IL-27 mediates complete regression of orthotopic primary and metastatic murine neuroblastoma tumors: role for CD8+ T cells. Journal of immunology 173, 7170–7182 (2004).
Chen, Q. et al. Interleukin-27 is a potent inhibitor of cis HIV-1 replication in monocyte-derived dendritic cells via a type I interferon-independent pathway. PloS one 8, e59194, doi: 10.1371/journal.pone.0059194 (2013).
Hu, P. et al. Expression of interleukins-23 and 27 leads to successful gene therapy of hepatocellular carcinoma. Molecular immunology 46, 1654–1662, doi: 10.1016/j.molimm.2009.02.025 (2009).
Matsui, M. et al. Interleukin-27 activates natural killer cells and suppresses NK-resistant head and neck squamous cell carcinoma through inducing antibody-dependent cellular cytotoxicity. Cancer research 69, 2523–2530, doi: 10.1158/0008-5472.can-08-2793 (2009).
Oniki, S. et al. Interleukin-23 and interleukin-27 exert quite different antitumor and vaccine effects on poorly immunogenic melanoma. Cancer research 66, 6395–6404, doi: 10.1158/0008-5472.can-05-4087 (2006).
Frank, A. C. et al. Interleukin-27, an anti-HIV-1 cytokine, inhibits replication of hepatitis C virus. J Interferon Cytokine Res 30, 427–431, doi: 10.1089/jir.2009.0093 (2010).
Yoshida, H. & Hunter, C. A. The immunobiology of interleukin-27. Annual review of immunology 33, 417–443, doi: 10.1146/annurev-immunol-032414-112134 (2015).
Pot, C., Apetoh, L., Awasthi, A. & Kuchroo, V. K. Induction of regulatory Tr1 cells and inhibition of T(H)17 cells by IL-27. Semin Immunol 23, 438–445, doi: 10.1016/j.smim.2011.08.003S1044-5323(11)00068-6 (2011).
Wojno, E. D. & Hunter, C. A. New directions in the basic and translational biology of interleukin-27. Trends Immunol 33, 91–97, doi: S1471-4906(11)00199-210.1016/j.it.2011.11.003 (2012).
Xu, M. et al. Regulation of antitumor immune responses by the IL-12 family cytokines, IL-12, IL-23, and IL-27. Clin Dev Immunol 2010, doi: 10.1155/2010/83245 (2010).
Brown, D. I. & Griendling, K. K. Nox proteins in signal transduction. Free Radic Biol Med 47, 1239–1253, doi: 10.1016/j.freeradbiomed.2009.07.023 (2009).
Leto, T. L. & Geiszt, M. Role of Nox family NADPH oxidases in host defense. Antioxid Redox Signal 8, 1549–1561, doi: 10.1089/ars.2006.8.1549 (2006).
Lambeth, J. D. NOX enzymes and the biology of reactive oxygen. Nat Rev Immunol 4, 181–189, doi: 10.1038/nri1312 (2004).
Abo, A. et al. Activation of the NADPH oxidase involves the small GTP-binding protein p21rac1. Nature 353, 668–670, doi: 10.1038/353668a0 (1991).
Zhao, X., Carnevale, K. A. & Cathcart, M. K. Human monocytes use Rac1, not Rac2, in the NADPH oxidase complex. J Biol Chem 278, 40788–40792, doi: 10.1074/jbc.M302208200 (2003).
Groemping, Y. & Rittinger, K. Activation and assembly of the NADPH oxidase: a structural perspective. The Biochemical journal 386, 401–416, doi: 10.1042/bj20041835 (2005).
Babior, B. M. NADPH oxidase. Curr Opin Immunol 16, 42–47 (2004).
Sumimoto, H. Structure, regulation and evolution of Nox-family NADPH oxidases that produce reactive oxygen species. FEBS J 275, 3249–3277, doi: 10.1111/j.1742-4658.2008.06488.x (2008).
Geissmann, F. et al. Development of monocytes, macrophages, and dendritic cells. Science (New York, N.Y.) 327, 656–661, doi: 10.1126/science.1178331 (2010).
Verreck, F. A. et al. Human IL-23-producing type 1 macrophages promote but IL-10-producing type 2 macrophages subvert immunity to (myco)bacteria. Proceedings of the National Academy of Sciences of the United States of America 101, 4560–4565, doi: 10.1073/pnas.0400983101 (2004).
Dai, L. et al. IL-27 inhibits HIV-1 infection in human macrophages by down-regulating host factor SPTBN1 during monocyte to macrophage differentiation. J Exp Med 210, 517–534, doi: 10.1084/jem.20120572 (2013).
Tan, H. Y. et al. The Reactive Oxygen Species in Macrophage Polarization: Reflecting Its Dual Role in Progression and Treatment of Human Diseases. Oxid Med Cell Longev 2016, 2795090, doi: 10.1155/2016/2795090 (2016).
Mills, E. L. & O’Neill, L. A. Reprogramming mitochondrial metabolism in macrophages as an anti-inflammatory signal. Eur J Immunol 46, 13–21, doi: 10.1002/eji.201445427 (2016).
Zhang, Y. et al. ROS play a critical role in the differentiation of alternatively activated macrophages and the occurrence of tumor-associated macrophages. Cell Res 23, 898–914, doi: 10.1038/cr.2013.75 (2013).
Stolk, J., Hiltermann, T. J., Dijkman, J. H. & Verhoeven, A. J. Characteristics of the inhibition of NADPH oxidase activation in neutrophils by apocynin, a methoxy-substituted catechol. American journal of respiratory cell and molecular biology 11, 95–102, doi: 10.1165/ajrcmb.11.1.8018341 (1994).
O’Donnell, B. V., Tew, D. G., Jones, O. T. & England, P. J. Studies on the inhibitory mechanism of iodonium compounds with special reference to neutrophil NADPH oxidase. The Biochemical journal 290, 41–49 (1993).
Fakruddin, J. M. et al. Noninfectious papilloma virus-like particles inhibit HIV-1 replication: implications for immune control of HIV-1 infection by IL-27. Blood 109, 1841–1849, doi: 10.1182/blood-2006-02-001578 (2007).
Imamichi, T., Yang, J., Huang da, W., Sherman, B. & Lempicki, R. A. Interleukin-27 induces interferon-inducible genes: analysis of gene expression profiles using Affymetrix microarray and DAVID. Methods Mol Biol 820, 25–53, doi: 10.1007/978-1-61779-439-1_3 (2012).
Imlay, J. A. Cellular defenses against superoxide and hydrogen peroxide. Annu Rev Biochem 77, 755–776, doi: 10.1146/annurev.biochem.77.061606.161055 (2008).
Zelko, I. N., Mariani, T. J. & Folz, R. J. Superoxide dismutase multigene family: a comparison of the CuZn-SOD (SOD1), Mn-SOD (SOD2), and EC-SOD (SOD3) gene structures, evolution, and expression. Free Radic Biol Med 33, 337–349 (2002).
Kuhns, D. B. et al. Residual NADPH oxidase and survival in chronic granulomatous disease. The New England journal of medicine 363, 2600–2610, doi: 10.1056/NEJMoa1007097 (2010).
Babior, B. M., Lambeth, J. D. & Nauseef, W. The neutrophil NADPH oxidase. Arch Biochem Biophys 397, 342–344, doi: 10.1006/abbi.2001.2642 (2002).
Elsen, S. et al. Cryptic O2–generating NADPH oxidase in dendritic cells. J Cell Sci 117, 2215–2226, doi: 10.1242/jcs.01085 (2004).
Marklund, S. L. Human copper-containing superoxide dismutase of high molecular weight. Proceedings of the National Academy of Sciences of the United States of America 79, 7634–7638 (1982).
Mizuguchi, S. et al. Carbon monoxide-releasing molecule CORM-3 suppresses vascular endothelial cell SOD-1/SOD-2 activity while up-regulating the cell surface levels of SOD-3 in a heparin-dependent manner. Free Radic Biol Med 49, 1534–1541, doi: 10.1016/j.freeradbiomed.2010.08.017 (2010).
Manni, M. L. et al. Extracellular superoxide dismutase in macrophages augments bacterial killing by promoting phagocytosis. Am J Pathol 178, 2752–2759, doi: 10.1016/j.ajpath.2011.02.007 (2011).
Gottfredsen, R. H. et al. The cellular distribution of extracellular superoxide dismutase in macrophages is altered by cellular activation but unaffected by the naturally occurring R213G substitution. Free Radic Biol Med 69, 348–356, doi: 10.1016/j.freeradbiomed.2014.01.038 (2014).
Mishra, M. K. & Yong, V. W. Myeloid cells - targets of medication in multiple sclerosis. Nat Rev Neurol 12, 539–551, doi: 10.1038/nrneurol.2016.110 (2016).
Collison, L. W. & Vignali, D. A. Interleukin-35: odd one out or part of the family? Immunological reviews 226, 248–262, doi: 10.1111/j.1600-065X.2008.00704.x (2008).
Taga, T. & Kishimoto, T. Gp130 and the interleukin-6 family of cytokines. Annual review of immunology 15, 797–819, doi: 10.1146/annurev.immunol.15.1.797 (1997).
Zhang, Q., Putheti, P., Zhou, Q., Liu, Q. & Gao, W. Structures and biological functions of IL-31 and IL-31 receptors. Cytokine & growth factor reviews 19, 347–356, doi: 10.1016/j.cytogfr.2008.08.003 (2008).
Meyer, D. M. et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690,550, in rat adjuvant-induced arthritis. J Inflamm 7, 41, doi: 10.1186/1476-9255-7-41 (2010).
Acknowledgements
Authors thank Dr. T. Kamata for discussion and B. Sherman for critical reading. This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products, or organizations imply endorsement by the U.S. Government. This research was supported [in part] by the National Institute of Allergy and Infectious Diseases.
Author information
Authors and Affiliations
Contributions
T.I. and Y.S. designed the study. B.S., Y.S., D.P., Q.C., T.S., H.I., and T.I. performed research, H.S. analyzed the data, D.B.K. provided western blot data from a C.D.G. patient, B.S., Y.S., D.P., H.C.L., and T.I. wrote the paper with critical input from S.S.D., D.B.K., N.N., and H.L.M. All authors approved the final version of the manuscript. B.S., Y.S., and D.P. contributed equally in this study.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Rights and permissions
This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
About this article
Cite this article
Sowrirajan, B., Saito, Y., Poudyal, D. et al. Interleukin-27 Enhances the Potential of Reactive Oxygen Species Generation from Monocyte-derived Macrophages and Dendritic cells by Induction of p47phox. Sci Rep 7, 43441 (2017). https://doi.org/10.1038/srep43441
Received:
Accepted:
Published:
DOI: https://doi.org/10.1038/srep43441
- Springer Nature Limited
This article is cited by
-
The cytokine IL-27 reduces inflammation and protects photoreceptors in a mouse model of retinal degeneration
Journal of Neuroinflammation (2022)
-
A novel microRNA, hsa-miR-6852 differentially regulated by Interleukin-27 induces necrosis in cervical cancer cells by downregulating the FoxM1 expression
Scientific Reports (2018)